The B7 family and cancer therapy: Costimulation and coinhibition

Xingxing Zang, James P. Allison

Research output: Contribution to journalArticle

234 Citations (Scopus)

Abstract

The activation and development of an adaptive immune response is initiated by the engagement of a T-cell antigen receptor by an antigenic peptide-MHCcom plex. The outcome of this engagement is determined by both positive and negative signals, costimulation and coinhibition, generated mainly by the interaction between the B7 family and their receptor CD28 family. The importance of costimulation and coinhibition of T cells in controlling immune responses is exploited by tumors as immune evasion pathways. Absence of the expression of costimulatory B7 molecules renders tumors invisible to the immune system, whereas enhanced expression of inhibitory B7 molecules protects them from effective T cell destruction. Therefore, the manipulation of these pathways is crucial for developing effective tumor immunotherapy. Translation of our basic knowledge of costimulation and coinhibition into early clinical trials has shown considerable promise.

Original languageEnglish (US)
Pages (from-to)5271-5279
Number of pages9
JournalClinical Cancer Research
Volume13
Issue number18
DOIs
StatePublished - Sep 15 2007
Externally publishedYes

Fingerprint

B7 Antigens
Family Therapy
Tumor Escape
T-Lymphocytes
Adaptive Immunity
T-Cell Antigen Receptor
Immunotherapy
Immune System
Neoplasms
Clinical Trials
Peptides

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The B7 family and cancer therapy : Costimulation and coinhibition. / Zang, Xingxing; Allison, James P.

In: Clinical Cancer Research, Vol. 13, No. 18, 15.09.2007, p. 5271-5279.

Research output: Contribution to journalArticle

Zang, Xingxing ; Allison, James P. / The B7 family and cancer therapy : Costimulation and coinhibition. In: Clinical Cancer Research. 2007 ; Vol. 13, No. 18. pp. 5271-5279.
@article{f45e708efe414b099c1a3057ffe80c82,
title = "The B7 family and cancer therapy: Costimulation and coinhibition",
abstract = "The activation and development of an adaptive immune response is initiated by the engagement of a T-cell antigen receptor by an antigenic peptide-MHCcom plex. The outcome of this engagement is determined by both positive and negative signals, costimulation and coinhibition, generated mainly by the interaction between the B7 family and their receptor CD28 family. The importance of costimulation and coinhibition of T cells in controlling immune responses is exploited by tumors as immune evasion pathways. Absence of the expression of costimulatory B7 molecules renders tumors invisible to the immune system, whereas enhanced expression of inhibitory B7 molecules protects them from effective T cell destruction. Therefore, the manipulation of these pathways is crucial for developing effective tumor immunotherapy. Translation of our basic knowledge of costimulation and coinhibition into early clinical trials has shown considerable promise.",
author = "Xingxing Zang and Allison, {James P.}",
year = "2007",
month = "9",
day = "15",
doi = "10.1158/1078-0432.CCR-07-1030",
language = "English (US)",
volume = "13",
pages = "5271--5279",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "18",

}

TY - JOUR

T1 - The B7 family and cancer therapy

T2 - Costimulation and coinhibition

AU - Zang, Xingxing

AU - Allison, James P.

PY - 2007/9/15

Y1 - 2007/9/15

N2 - The activation and development of an adaptive immune response is initiated by the engagement of a T-cell antigen receptor by an antigenic peptide-MHCcom plex. The outcome of this engagement is determined by both positive and negative signals, costimulation and coinhibition, generated mainly by the interaction between the B7 family and their receptor CD28 family. The importance of costimulation and coinhibition of T cells in controlling immune responses is exploited by tumors as immune evasion pathways. Absence of the expression of costimulatory B7 molecules renders tumors invisible to the immune system, whereas enhanced expression of inhibitory B7 molecules protects them from effective T cell destruction. Therefore, the manipulation of these pathways is crucial for developing effective tumor immunotherapy. Translation of our basic knowledge of costimulation and coinhibition into early clinical trials has shown considerable promise.

AB - The activation and development of an adaptive immune response is initiated by the engagement of a T-cell antigen receptor by an antigenic peptide-MHCcom plex. The outcome of this engagement is determined by both positive and negative signals, costimulation and coinhibition, generated mainly by the interaction between the B7 family and their receptor CD28 family. The importance of costimulation and coinhibition of T cells in controlling immune responses is exploited by tumors as immune evasion pathways. Absence of the expression of costimulatory B7 molecules renders tumors invisible to the immune system, whereas enhanced expression of inhibitory B7 molecules protects them from effective T cell destruction. Therefore, the manipulation of these pathways is crucial for developing effective tumor immunotherapy. Translation of our basic knowledge of costimulation and coinhibition into early clinical trials has shown considerable promise.

UR - http://www.scopus.com/inward/record.url?scp=34848831575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34848831575&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-07-1030

DO - 10.1158/1078-0432.CCR-07-1030

M3 - Article

C2 - 17875755

AN - SCOPUS:34848831575

VL - 13

SP - 5271

EP - 5279

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 18

ER -